Literature DB >> 29844071

Hypertension in China: Time to Transition From Knowing the Problem to Implementing the Solution.

Norman R C Campbell1, Xin-Hua Zhang2.   

Abstract

Entities:  

Keywords:  China; Editorials; blood pressure; hypertension

Mesh：

Year:  2018        PMID： 29844071     DOI： 10.1161/CIRCULATIONAHA.118.034028

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

1.  Deaths from total and premature cardiovascular disease associated with high normal blood pressure and hypertension in rural Chinese men and elderly people.

Authors:  Leilei Liu; Yu Liu; Yongcheng Ren; Yang Zhao; Pei Qin; Dechen Liu; Xu Chen; Cheng Cheng; Feiyan Liu; Chunmei Guo; Qionggui Zhou; Quanman Li; Gang Tian; Minghui Han; Ranran Qie; Xiaoyan Wu; Shengbing Huang; Xinping Luo; Ruirong Cheng; Dongsheng Hu; Jian Wang; Ming Zhang
Journal:  J Hum Hypertens       Date:  2020-07-20       Impact factor: 3.012

2.  A Study of Machine-Learning Classifiers for Hypertension Based on Radial Pulse Wave.

Authors:  Zhi-Yu Luo; Ji Cui; Xiao-Juan Hu; Li-Ping Tu; Hai-Dan Liu; Wen Jiao; Ling-Zhi Zeng; Cong-Cong Jing; Li-Jie Qiao; Xu-Xiang Ma; Yu Wang; Jue Wang; Ching-Hsuan Pai; Zhen Qi; Zhi-Feng Zhang; Jia-Tuo Xu
Journal:  Biomed Res Int       Date:  2018-11-11       Impact factor: 3.411

3.  Visceral fat reduction is positively associated with blood pressure reduction in overweight or obese males but not females: an observational study.

Authors:  Xiaohui Guo; Yifan Xu; Hairong He; Hao Cai; Jianfen Zhang; Yibin Li; Xinyu Yan; Man Zhang; Na Zhang; Rolando L Maddela; Guansheng Ma
Journal:  Nutr Metab (Lond)       Date:  2019-07-10       Impact factor: 4.169

4.  Neck circumference as an indicator of elevated blood pressure independent from body composition: implications from the China nation health survey (CNHS).

Authors:  Huijing He; Li Pan; Feng Liu; Jingang Ma; Li Wang; Zhiping Hu; Yajun Li; Guangliang Shan
Journal:  BMC Cardiovasc Disord       Date:  2019-11-06       Impact factor: 2.298

5.  Regularity of Clinical Visits and Medication Adherence of Patients with Hypertension or Diabetes in Rural Yunnan Province of China.

Authors:  Qiufeng Gao; Lanxi Peng; Wenbin Min; Jingchun Nie; Aiqin Wang; Yaojiang Shi; Haonan Shi; Dirk E Teuwen; Hongmei Yi
Journal:  Int J Environ Res Public Health       Date:  2020-12-12       Impact factor: 3.390

6.  Association of Depression with Uncontrolled Hypertension in Primary Care Setting: A Cross-Sectional Study in Less-Developed Northwest China.

Authors:  Lin Wang; Nanfang Li; Mulalibieke Heizhati; Mei Li; Zhikang Yang; Zhongrong Wang; Reyila Abudereyimu
Journal:  Int J Hypertens       Date:  2021-03-27       Impact factor: 2.420

7.  Excess weight loss is a vital strategy for controlling hypertension among multi-ethnic population in northwest China: A cross-sectional analysis.

Authors:  Lin Wang; Mulalibieke Heizhati; Delian Zhang; Guijuan Chang; Xiaoguang Yao; Jing Hong; Mayila Kamilijiang; Mei Li; Nanfang Li
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

8.  Chart review of patients receiving valsartan-amlodipine single-pill combination versus valsartan and amlodipine combination for blood pressure goal achievement and effects on the Hamilton anxiety rating/Hamilton depression rating scales.

Authors:  Gang Yin; Yuefan Li; Wenjie Xu; Na Han
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

9.  Trends and Inequalities in the Health Care and Hypertension Outcomes in China, 2011 to 2015.

Authors:  Yang Zhao; Ajay Singh Mahal; Tilahun Nigatu Haregu; Ameera Katar; Brian Oldenburg; Luwen Zhang
Journal:  Int J Environ Res Public Health       Date:  2019-11-19       Impact factor: 3.390

Review 10.  Hypertension in China: burdens, guidelines and policy responses: a state-of-the-art review.

Authors:  Ruoyu Yin; Lishi Yin; Lin Li; Jennifer Silva-Nash; Jingru Tan; Zixian Pan; Jianying Zeng; Lijing L Yan
Journal:  J Hum Hypertens       Date:  2021-07-02       Impact factor: 2.877
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.